Spineway: Half-yearly review 2025 and outlook

Spineway, a company specializing in implants for severe spinal pathologies, has unveiled its half-year results for 2025. Revenue stood at €5.6 million, down from the previous year. However, gross margin climbed to 69% and net operating costs decreased by 3% thanks to cost-cutting measures.

Net income, although still negative at -€1.4 million, improved by €2 million compared to 2024. The reduction in financial expenses related to the contract with Negma contributed to this improvement. Spineway has a solid cash position of €4 million and debt of €1.5 million, leaving a net cash position of €2.5 million.

The company confirms its growth target for 2025, supported by an international training program and the launch of new products in Indonesia. Spineway approaches the second half of the year with optimism and solid financial foundations.